Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04643769
Recruitment Status : Recruiting
First Posted : November 25, 2020
Last Update Posted : February 12, 2021
Sponsor:
Collaborator:
Vanderbilt University
Information provided by (Responsible Party):
Orinove, Inc.

Brief Summary:

This Phase 1b trial is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of oral ORIN1001 at 25 mg, 50 mg or 100 mg administered daily for up to 28 days in adult subjects with idiopathic pulmonary fibrosis (IPF) alone or in conjunction with local Standard of Care for IPF (pirfenidone or nintedanib).

A maximum of 24 evaluable subjects will be required to complete the study. The study will consist of 3 dose cohorts each enrolling a maximum of 8 subjects randomized either to the active (5 subjects) group or placebo (3 subjects) group. Each subject will receive daily oral doses of ORIN1001 or placebo for 28 days.

The safety and pharmacokinetic profile will be evaluated in this study and will include cardiovascular and pulmonary endpoints.


Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: ORIN1001 Drug: Placebo Phase 1

Detailed Description:

This Phase 1b trial is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of oral ORIN1001 at 25 mg, 50 mg or 100 mg administered daily for up to 28 days in adult subjects with idiopathic pulmonary fibrosis (IPF) alone or in conjunction with local standard of care (SOC) for IPF (i.e., pirfenidone or nintedanib).

Approximately 24 evaluable subjects will be required for this study. Eligible subjects will be followed for safety through the dose-limiting toxicity (DLT) evaluation period, defined as 28 days after the first dose of ORIN1001.

In the absence of intolerable toxicity, doses will be escalated sequentially with 8 evaluable subjects receiving a maximum of 28 days of ORIN1001 in once-daily doses of 25 mg (Cohort 1), 50 mg (Cohort 2), or 100 mg (Cohort 3) versus matched placebo. Subjects will be stratified based on local SOC for IPF, defined as the stable daily dose of pirfenidone or nintedanib (or neither) received for at least 8 weeks prior to signing the Informed Consent Form (ICF). ORIN1001 or matched placebo will be administered daily until Day 28, unacceptable toxicity, withdrawal for another reason or study termination.

Safety Endpoints will be evaluated and will include adverse events (AEs), serious adverse events (SAEs), and changes in clinical laboratory evaluations as compared to baseline. Safety variables include but are not limited to: vital signs (blood pressure [BP], heart rate [HR], respiratory rate [RR]) and temperature; twelve-lead ECG; clinical laboratory tests (hematology, coagulation profile, clinical chemistry, and urinalysis); concomitant medications; physical examination; body weight; and pulmonary function tests (forced vital capacity [FVC], forced expiratory volume [FEV], and diffusion capacity [DLCO]) at baseline, End-of- Treatment and Follow-up Visits.

Pharmacokinetic (PK) Endpoints will be evaluated on Day 1 and Day 28 and blood collection samples will be obtained from each subject. Exploratory serum biomarker endpoints will be evaluated to assess lung fibrosis and inflammation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Placebo-controlled, double blind
Primary Purpose: Treatment
Official Title: Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Actual Study Start Date : February 9, 2021
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : December 30, 2021


Arm Intervention/treatment
Experimental: 25 mg ORIN1001 (Active)
25 mg ORIN1001
Drug: ORIN1001
Oral tablet - ORIN1001

Experimental: 50 mg ORIN1001 (active)
50 mg ORIN1001
Drug: ORIN1001
Oral tablet - ORIN1001

Experimental: 100 mg ORIN1001 (active)
100 mg ORIN1001
Drug: ORIN1001
Oral tablet - ORIN1001

Placebo Comparator: Placebo - 25 mg
Placebo comparator for ORIN1001 at 25 mg
Drug: Placebo
Oral tablet - placebo

Placebo Comparator: Placebo - 50 mg
Placebo comparator for ORIN1001 at 50 mg
Drug: Placebo
Oral tablet - placebo

Placebo Comparator: Placebo - 100 mg
Placebo comparator for ORIN1001 at 100 mg
Drug: Placebo
Oral tablet - placebo




Primary Outcome Measures :
  1. Blood pressure [ Time Frame: Up to 60 days ]
    measurement of blood pressure

  2. Heart Rate [ Time Frame: Up to 60 days ]
    measurement of heart rate

  3. Respiratory Rate [ Time Frame: Up to 60 days ]
    Measurement of respiratory rate

  4. Body Temperature [ Time Frame: Up to 60 days ]
    Measurement of body temperature

  5. 12-lead ECG [ Time Frame: Up to 60 days ]
    Cardiovascular evaluation to determine intervals including QTc interval

  6. Serum Clinical Chemistry analysis [ Time Frame: Up to 60 days ]
    ALT, albumin, ALP, AST, BUN, Ca, Cl, Cholesterol, Creatinine, CK, CA, Elastase, GGT, glucose, HDL, LDH, lipase, LDL, phosphorus, sodium, Total bilirubin, Total protein, Triglycerides, Uric acid, Lipid panel

  7. Whole blood Hematology analysis [ Time Frame: Up to 60 dys ]
    WBC, RBC, Hb, HCT, MCV, MCH, MCHC, Neu, Lymphocytes, EOS, Bas, PLT

  8. Whole blood Coagulation Parameters [ Time Frame: Up to 60 days ]
    PT, APTT, INR

  9. Urinalysis [ Time Frame: Up to 60 days ]
    Bilrubin, glusoe, ketones, leukocytes, nitrite, blood, pH, specific gravity, protein, urobilinogen

  10. Concomitant medications [ Time Frame: Up to 60 days ]
    Evaluation of other medications taken currently with investigative drug

  11. Physical examination [ Time Frame: Up to 60 days ]
    Medical Health examination, medical history, medicine history, reproductive history, baseline information

  12. Body weight [ Time Frame: Up to 60 days ]
    Body weight in kg

  13. Spirometry [ Time Frame: Up to 60 days ]
    Pulmonary Function Tests: Forced vital capacity (FVC), Forced expiratory volume (FEV)

  14. Height [ Time Frame: Up to 60 days ]
    Height in cm

  15. Body mass index (BMI) [ Time Frame: Up to 60 days ]
    Calculation of BMI using weight (kg) and height (cm)

  16. DLCO - Assessment of diffusion capacity [ Time Frame: Up to 60 days ]
    Lung test to assess diffusion capacity


Secondary Outcome Measures :
  1. Blood collection to measure drug concentration over time [ Time Frame: Up to 29 days ]
    Blood collection for evaluation of ORIN1001 exposure. Measurements will assess half life, exposure, maximum concentration, time to maximum concentration and accumulation ratios


Other Outcome Measures:
  1. Exploratory biomarkers to evaluate lung fibrosis [ Time Frame: Up to 60 days ]
    Blood collection for evaluation of disease biomarker of lung fibrosis: SP-D, MMP-7 and KL6. Specific biomarker to be determined

  2. Quality of Life Questionnaire [ Time Frame: Up to 60 days ]
    Questionnaire to assess the quality of life during the study period

  3. Exploratory biomarkers to evaluate inflammation [ Time Frame: Up to 60 days ]
    Blood collection for evaluation of inflammation such as cytokines TGF-B and/or IL-6



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 40-80 years of age (inclusive) when signing the Informed Consent.
  2. Diagnosis of IPF or likely IPF per 2018 American Thoracic Society and European Respiratory Society (ATS/ERS) criteria:

    • Study Investigator will confirm IPF diagnosis based on Interstitial Lung Disease (ILD) in consultation with relevant experts through a review of the subject's history, high-resolution computerized tomography (HRCT) scan, and lung biopsy (if applicable).
    • A lung biopsy is not required in the setting of a compatible clinical history and usual interstitial pneumonia (UIP) or probable UIP per HRCT.
    • Study Investigators will verify that a diagnosis of IPF and an HRCT were obtained within 7 years prior to signing the ICF.
  3. Continued SOC IPF therapy (consisting of pirfenidone [Esbriet®] OR nintedanib [Ofev®] OR neither) is acceptable, provided stable dosing of the drug for at least 8 consecutive weeks immediately prior to signing the ICF.
  4. The effect of ORIN1001 on the developing human fetus, if any, is unknown. Therefore, for the duration of study participation:

    • Women who are postmenopausal for < 1 year before the Screening and not otherwise sterile (e.g., due to a surgical procedure) may be considered of child-bearing potential and require a negative pregnancy test prior to study registration. They must agree to (a) use effective contraception (i.e., hormonal or barrier method of birth control when engaged in heterosexual intercourse) or (b) abstinence throughout the study period AND for 4 weeks after final dosing with the IMP.
    • Men who are not otherwise sterile (e.g., due to a surgical procedure) must agree not to donate sperm and use effective contraception (i.e.,hormonal or barrier method of birth control when engaged in heterosexual intercourse) or abstinence throughout the study period AND for at least 16 weeks (due to the sperm life cycle) after final dosing with the IMP.
  5. Written informed consent must be given prior to any study-related procedure that is not part of standard medical care, understanding that the subject may withdraw it at any time without prejudice to future treatment.

Exclusion Criteria:

  1. Screening lab values that fail to meet the following criteria will render the subject ineligible for study participation:

    • Platelet count <100 × 109/L. Repeat measurements may be performed, but transfusion, in order to meet eligibility criteria, is not allowed.
    • Hemoglobin <12.9 g/dL (men) and <11.9 g/dL (women).
    • Prothrombin time (PT) or partial thromboplastin time (PTT) >1.5 × upper limit of normal; international normalized ratio (INR) >2.
    • Aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >1.5 × upper limit of normal (ULN).
    • Serum glutamic-oxaloacetic transaminase [SGOT] or serum glutamic pyruvic transaminase [SGPT]) >2.0 × ULN.
    • Kidney disease with estimated glomerular filtration rate <60 mL/min).
  2. Forced vital capacity (FVC) ≤40% of predicted normal per site pulmonary function lab protocol.
  3. Diffusing capacity of the lungs for carbon monoxide (DLCO) ≤30% of predicted normal as calculated according to the site pulmonary function lab protocol.
  4. Forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio < 0.7.
  5. Documented IPF exacerbation within 3 months of signing the ICF (e.g., >5% or 10% change in FVC and DLCO, respectively).
  6. Listing for lung transplantation, defined as the assignment of a lung allocation score or acceptance on the waiting list for lung transplantation.
  7. Current and/or uncontrolled cardiovascular condition (e.g., clinically significant arrhythmia or hypertension), >Class II heart failure per New York Heart Association criteria, unstable angina, myocardial infarction, coronary syndrome) within 6 months of Screening which, as judged by the Investigator, might put the subject at risk because of participation in the study.
  8. Known cirrhotic liver, chronic liver, or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones). Liver cirrhosis with portal hypertension and active liver infection are exclusionary (note: cured hepatitis C is not considered active).
  9. Gastrointestinal disease (e.g., active bleeding or ulcers) or procedure that could interfere with oral absorption or tolerance of the IMP, including difficulty swallowing.
  10. Diarrhea >Grade 1 (i.e., increase of >4 stools per day OR >1 watery stool per day OR moderate increase in ostomy output compared to baseline) will render a subject ineligible for participation in this study. Anti-diarrheal medication (e.g., loperamide, sold under the brand name Imodium®, among others) is allowed.
  11. Active malignancy within the past 12 months or ongoing active cancer treatment (surgery, radiotherapy, chemotherapy or immunotherapy), except for adequately treated Stage 1 cancer, nonmelanoma skin cancer, or in situ cervical cancer. Cancer in complete remission or requiring only maintenance therapy (e.g., tamoxifen for breast cancer) is not considered active.
  12. Known bleeding risk due to platelet dysfunction, or inherited or acquired clotting factor deficiency (e.g., von Willebrand disease, hemophilia).
  13. Major trauma or surgery including but not limited to operations involving a major organ (e.g., the cranium, chest, abdomen, or pelvic cavity) OR requiring a lengthy recovery period (e.g., arthroplasty) within 3 months of signing the ICF; or expected surgery during the trial period.
  14. Central nervous system hemorrhagic event within 12 months of signing ICF; brain arterio-venous malformation (AVM) or moderate-to-severe ischemic stroke within 6 months of signing ICF.
  15. Concurrent use of full-dose therapeutic anti-coagulation (e.g., vitamin K antagonist, dabigatran, hirudin, direct factor Xa inhibitors) or high dose anti-platelet therapy. Aspirin <81 mg/day, prophylactic subcutaneous (SC) heparin or SC low-molecular weight heparin for deep vein thrombosis prophylaxis or heparin flush to maintain intravenous catheter patency are allowed.
  16. Long-term use of nonsteroidal anti-inflammatory agents, defined as >4 days per week.
  17. Receipt of hematopoietic growth factors, blood or blood product transfusion within 1 week of the first dose of IMP.
  18. Disqualifying treatments within 60 days or 5 half-lives (whichever is longer) from Randomization include:

    • Systemic corticosteroids (>10 mg prednisone or equivalent).
    • Systemic immunosuppressive therapy.
    • Investigational agent other than study IMP.
  19. Recreational drug use (including amphetamines, cocaine, barbiturates, opiates, benzodiazepines, phencyclidine, and cannabinoids) for the duration of study participation.
  20. Clinically significant laboratory abnormality, medical or psychological comorbidity, or concurrent medication that could compromise subject safety, data integrity or requirements for study participation, per site Investigator in consultation with the Sponsor.
  21. Inability to attend in-person appointments per current clinical site COVID-19 guidelines and restrictions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04643769


Contacts
Layout table for location contacts
Contact: Maria M Corvez, MD 617-702-8785 mariacorvez@fosunpharma.com
Contact: Stephanie Greene, PhD 805-231-8108 sgreene@orinove.com

Locations
Layout table for location information
United States, Florida
St. Francis Sleep, Allergy & Lung Institute Recruiting
Clearwater, Florida, United States, 33765
Contact: Ann Gove, RN    727-210-4606    agove@stfrancismed.com   
Contact: Amber Dunn, RN    727-210-4606    adunn@stfrancismed.com   
Sponsors and Collaborators
Orinove, Inc.
Vanderbilt University
Investigators
Layout table for investigator information
Principal Investigator: Frank Averill, MD Sleep, Allergy and Lung Institute
Layout table for additonal information
Responsible Party: Orinove, Inc.
ClinicalTrials.gov Identifier: NCT04643769    
Other Study ID Numbers: ORIN1001-002
First Posted: November 25, 2020    Key Record Dates
Last Update Posted: February 12, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial